In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil

Cornea

Volumn 24, Issue 6, 2005, Pages 730-734

  Höfling Lima, Ana Luisa ^a,b   De Freitas, Denise ^a   Sampaio, Jorge Luiz Mello ^a   Leão, Sylvia Cardoso ^a   Contarini, Patrícia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Fluoroquinolones; Infectious keratitis; LASIK; Mycobacterium abscessus; Mycobacterium chelonae

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BRAZIL; DRUG ACTIVITY; KERATITIS; KERATOMILEUSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYOPIA; NONHUMAN; PRIORITY JOURNAL;

ADULT; BRAZIL; COLONY COUNT, MICROBIAL; CORNEAL ULCER; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; HUMANS; KERATOMILEUSIS, LASER IN SITU; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYOPIA; SURGICAL WOUND INFECTION;

EID: 23044447412     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000154411.07315.0a     Document Type: Article

References (74)

1. Carpel EF, Carlson KH, Shannon S. Fine lattice lines on the corneal surface after laser in situ keratomileusis (LASIK). Am J Ophthalmol. 2000;129:379-380.
2. Hernandez-Matamoros J, Iradier MT, Moreno E. Treating folds and striae after laser in situ keratomileusis. J Cataract Refract Surg. 2001;27: 350-352.
3. Recep OF, Cagil N, Hasiripi H. Outcome of flap subluxation after laser in situ keratomileusis: results of 6 month follow-up. J Cataract Refract Surg. 2000;26:1158-1162.
4. Leung AT, Rao SK, Lam DS. Flap complications associated with lamellar refractive surgery. Am J Ophthalmol. 2000;130:258-259.
5. Wright JD Jr, Neubaur CC, Stevens G Jr. Epithelial ingrowth in a corneal graft treated by laser in situ keratomileusis: light and electron microscopy. J Cataract Refract Surg. 2000;26:49-55.
6. Parolini B, Marcon G, Panozzo GA. Central necrotic lamellar inflammation after laser in situ keratomileusis. J Refract Surg. 2001;17:110-112.
7. Macaluso DC, Rich LF, MacRae S. Sterile interface keratitis after laser in situ keratomileusis: three episodes in one patient with concomitant contact dermatitis of the eyelids. J Refract Surg. 1999;15:679-682.
8. Smith RJ, Maloney RK. Diffuse lamellar keratitis. A new syndrome in lamellar refractive surgery. Ophthalmology. 1998;105:1721-1726.
9. Alio JL, Belda JI, Shalaby AM. Correction of irregular astigmatism with excimer laser assisted by sodium hyaluronate. Ophthalmology. 2001;108:1246-1260.
10. Duncker GI, Amm M, Schroder E. The problem of undercorrection after laser in situ keratomileusis: an explanation. J Refract Surg. 1996; 12:454.
11. Rowsey JJ, Rubin ML. Refraction problems after refractive surgery. Surv Ophthalmol. 1988;32:414-420.
12. Johnson JD, Azar DT. Surgically induced topographical abnormalities after LASIK: management of central islands, corneal ectasia, decentration, and irregular astigmatism. Curr Opin Ophthalmol. 2001;12: 309-317.
13. Patel S, Perez-Santonja JJ, Alio JL, et al. Corneal sensitivity and some properties of the tear film after laser in situ keratomileusis. J Refract Surg. 2001;17:17-24.
14. Kim WS, Kim JS. Change in corneal sensitivity following laser in situ keratomileusis. J Cataract Refract Surg. 1999;25:368-373.
15. Haw WW, Manche EE. Late onset diffuse lamellar keratitis associated with an epithelial defect in six eyes. J Refract Surg. 2000;16:744-748.
16. Webber SK, Lawless MA, Sutton GL, et al. Staphylococcal infection under a LASIK flap. Cornea. 1999;18:361-365.
17. Karp KO, Hersh PS, Epstein RJ. Delayed keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2000;26:925-928.
18. Nascimento EG, Carvalho MJ, Freitas D, et al. Nocardial keratitis following myopic keratomileusis. J Refract Surg. 1995;11:210-211.
19. Perez-Santonja JJ, Sakla HF, Abad JL, et al. Nocardial keratitis after laser in situ keratomileusis. J Refract Surg. 1997;13:314-317.
20. Kuo IC, Margolis TP, Cevallos V, et al. Aspergillus fumigatus keratitis after laser in situ keratomileusis. Cornea. 2001;20:342-344.
21. Davidorf JM. Herpes simplex keratitis after LASIK. J Refract Surg. 1998;14:667.
22. Gupta V, Dada T, Vajpayee RB, et al. Polymicrobial keratitis after laser in situ keratomileusis. J Refract Surg. 2001;17:147-148.
23. Jain S, Azar DT. Eye infections after refractive keratotomy. J Refract Surg. 1996;12:148-155.
24. Quiros PA, Chuck RS, Smith RE, et al. Infectious ulcerative keratitis after laser in situ keratomileusis. Arch Ophthalmol. 1999;117:1423-1427.
25. Garg P, Bansal AK, Sharma S, et al. Bilateral infectious keratitis after laser in situ keratomileusis: a case report and review of the literature. Ophthalmology. 2001;108:121-125.
26. Watanabe H, Sato S, Maeda N, et al. Bilateral corneal infection as a complication of laser in situ keratomileusis. Arch Ophthalmol. 1997; 115:1593-1594.
27. Chandra NS, Torres MF, Winthrop KL, et al. Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis. Am J Ophthalmol. 2001;132:819-830.
28. Holmes GP, Bond GB, Fader RC, et al. A cluster of cases of Mycobacterium szulgai keratitis that occurred after laser-assisted in situ keratomileusis. Clin Infect Dis. 2002;34:1039-1046.
29. Kim HM, Song JS, Han HS, et al. Streptococcal keratitis after myopic laser in situ keratomileusis. Korean J Ophthalmol. 1998;12:108-111.
30. Brown-Elliott BA, Wallace RJ Jr, Crist CJ, et al. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother. 2002;46:3283-3285.
31. Reviglio V, Rodriguez ML, Picotti GS, et al. Mycobacterium chelonae keratitis following laser in situ keratomileusis. J Refract Surg. 1998;14: 357-360.
32. Hu FR. Extensive lamellar keratectomy for treatment of nontuberculous mycobacterial keratitis. Am J Ophthalmol. 1995;120:47-54.
33. Giaconi J, Pham R, Ta CN. Bilateral Mycobacterium abscessus keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2002;28: 887-890.
34. Alvarenga L, Freitas D, Hofling-Lima AL, et al. Infectious post-LASIK crystalline keratopathy caused by nontuberculous mycobacteria. Cornea. 2002;21:426-429.
35. Seo KY, Lee JB, Lee K, et al. Non-tuberculous mycobacterial keratitis at the interface after laser in situ keratomileusis. J Refract Surg. 2002;18: 81-85.
36. Solomon A, Karp CL, Miller D, et al. Mycobacterium interface keratitis after laser in situ keratomileusis. Ophthalmology. 2001;108:2201-2208.
37. Busin M, Ponzin D, Arffa RC. Mycobacterium chelonae interface infection after endokeratoplasty. Am J Ophthalmol. 2003;135:393-395.
38. Pache M, Schipper I, Flammer J, et al. Unilateral fungal and mycobacterial keratitis after simultaneous laser in situ keratomileusis. Cornea. 2003; 22:72-75.
39. Suresh PS, Campbell I, Herzig S, et al. Mycobacterium keratitis following hyperopic laser in situ keratomileusis. Can J Ophthalmol. 2001;36: 272-274.
40. Matoba A. Mycobacterium chelonae keratitis. Am J Ophthalmol. 1987; 103:595-596.
41. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112(4 Suppl):29S-33S.
42. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313-1318.
43. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991;112(4 Suppl):34S-47S.
44. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996;121:712-715.
45. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol. 1991;112(4 Suppl):15S-24S.
46. Green LC, Callegan MC, Engel LS, et al. Pharmacokinetics of topically applied ciprofloxacin in rabbit tears. Jpn J Ophthalmol. 1996;40:123-126.
47. Donnenfeld ED, Schrier A, Perry HD, et al. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology. 1994;101:902-905.
48. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995;113:1257-1265.
49. Serdarevic ON. Role of the fluoroquinolones in ophthalmology. Int Ophthalmol Clin. 1993;33:163-178.
50. Chung MS, Goldstein MH, Driebe WT Jr, et al. Mycobacterium chelonae keratitis after laser in situ keratomileusis successfully treated with medical therapy and flap removal. Am J Ophthalmol. 2000;129:382-384.
51. Hwang DG, Biswell R. Ciprofloxacin therapy of Mycobacterium chelonae keratitis. Am J Ophthalmol. 1993;115:114-115.
52. Wallace RJ Jr, Swenson JM, Silcox VA. The rapidly growing mycobacteria: characterization and susceptibility testing. Antimicrob Newsl. 2:85-92.
53. Lin R, Holland GN, Helm CJ, et al. Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis in an animal model. Am J Ophthalmol. 1994;117: 657-662.
54. Matoba AY, Lee BL, Robinson NM, et al. Combination drug testing of Mycobacterium chelonae. Invest Ophthalmol Vis Sci. 1993;34:2786-2789.
55. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716-746.
56. Braback M, Riesbeck K, Forsgren A. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother. 2002;46:1114-1116.
57. Fulcher SF, Fader RC, Rosa RH Jr, et al. Delayed-onset mycobacterial keratitis after LASIK. Cornea. 2002;21:546-554.
58. Tebas P, Sultan F, Wallace RJ Jr, et al. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis. 1995;20: 443-444.
59. Huang SC, Soong HK, Chang JS, et al. Non-tuberculous mycobacterial keratitis: a study of 22 cases. Br J Ophthalmol. 1996;80:962-968.
60. Freitas D, Alvarenga L, Sampaio J, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology. 2003;110: 276-285.
61. Mulhern MG, Condon PI, O'Keefe M. Endophthalmitis after astigmatic myopic laser in situ keratomileusis. J Cataract Refract Surg. 1997; 23:948-950.
62. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40: 639-651.
63. Jones RN, Pfaller MA. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99). Diagn Microbiol Infect Dis. 2001;39:237-243.
64. Rodriguez Diaz JC, Lopez M, Ruiz M, et al. in vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents. 2003;21:585-588.
65. Telenti A, Marchesi F, Balz M, et al. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol. 1993;31:175-178.
66. Roth A, Reischl U, Streubel A, et al. Novel diagnostic algorithm for identification of mycobacteria using genus-specific amplification of the 16S-23S rRNA gene spacer and restriction endonucleases. J Clin Microbiol. 2000;38:1094-1104.
67. NCCL NCfCLS. Perfomance Standards for Antimicrobial Susceptibility Testing, 12th Informational Supplement M100-S12. Wayne: NCCLS. 2002.
68. NCCL NCfCLS. Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes. Wayne: NCCLS. 2003.
69. Bullington RH Jr, Lanier JD, Font RL. Nontuberculous mycobacterial keratitis. Report of two cases and review of the literature. Arch Ophthalmol. 1992;110:519-524.
70. Rikimaru T, Kondo M, Kondo S, et al. Bactericidal activities of povidoneiodine against Mycobacterium. Dermatology. 1997;195(Suppl 2):104-106.
71. Ford JG, Huang AJ, Pflugfelder SC, et al. Nontuberculous mycobacterial keratitis in South Florida. Ophthalmology. 1998;105:1652-1658.
72. Woods GL. The mycobacteriology laboratory and new diagnostic techniques. Infect Dis Clin North Am. 2002;16:127-144.
73. Woods GL, Bergmann JS, Witebsky FG, et al. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol. 2000; 38:656-661.
74. Hu FR, Wang IJ. Comparison of topical antibiotics for treating Mycobacterium chelonae keratitis in a rabbit model. Curr Eye Res. 1998;17:478-482.